Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Peer Review reports

Original Submission
21 Nov 2017	Submitted	Original manuscript
27 Dec 2017	Author responded	Author comments - Taro Iguchi
Resubmission - Version 2
27 Dec 2017	Submitted	Manuscript version 2
26 Jul 2018	Reviewed	Reviewer Report - Rahul Aggarwal
19 Jan 2019	Reviewed	Reviewer Report - Laurence Krieger
6 Feb 2019	Author responded	Author comments - Taro Iguchi
Resubmission - Version 3
6 Feb 2019	Submitted	Manuscript version 3
20 Mar 2019	Reviewed	Reviewer Report - Laurence Krieger
25 Mar 2019	Author responded	Author comments - Taro Iguchi
Resubmission - Version 4
25 Mar 2019	Submitted	Manuscript version 4
Publishing
27 Mar 2019	Editorially accepted
11 Apr 2019	Article published	10.1186/s12885-019-5526-3

Back to article page